Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06925360
PHASE2

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

Sponsor: International Peace Maternity and Child Health Hospital

View on ClinicalTrials.gov

Summary

It is intended to examine the efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.

Official title: The Efficacy of Intravenous Immunoglobulin for the Treatment of Bronchopulmonary Dysplasia

Key Details

Gender

All

Age Range

Any - 10 Weeks

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-04-12

Completion Date

2027-12

Last Updated

2026-04-01

Healthy Volunteers

Yes

Interventions

DRUG

intravenous immunoglobulin

1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.

Locations (1)

International Peace Maternity and Child Health Hospital

Shanghai, Shanghai Municipality, China